ClinicalTrials.gg
CompletedNCT04659031Updated Feb 20, 2025

A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients with (IBM)

A Phase 1 interventional study of ABC008 in Inclusion Body Myositis, sponsored by Abcuro, Inc.. Completed at 4 sites in Australia. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by Abcuro, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
40 Years and older
Sex
All
01

Study summary

An open-label, ascending dose study for adult patients with Inclusion Body Myositis (IBM).

Read the detailed description

Participants who successfully complete the SAD EOT visit, and have no emerging safety issues, will be eligible to enroll in Part 2 (MAD). Eligible participants for the MAD part will have inclusion and exclusion criteria (same as those for Part 1) reviewed prior to dosing on MAD Day 1.

Participants who successfully complete the MAD EOT visit, and have no emerging safety issues, will be eligible to enrol in Part 3, MAD Extension.

After the final MAD visit (W48), participants will have the option to continue on to Part 3 MAD Extension.

For Part 3 (MAD Extension), participant dosing will be at 8-week intervals starting at Day 1. Duration of dosing in Part 3 will be up to approximately 80 weeks (18 months), or until a new long-term extension study has been initiated. The SMC will review all participant safety data approximately every 6 months while the Part 3 dosing continues.

02

Conditions studied

  • Inclusion Body Myositis

Keywords

  • Inclusion Body Myositis
  • IBM
03

In context

Myositis, Inclusion Body

65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.

This study's enrollment of 19 is below the median of 30 across 42 interventional studies indexed under Myositis, Inclusion Body.

Browse Myositis, Inclusion Body studies →

Lead sponsor

Abcuro, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of either clinico- defined IBM, clinically defined IBM, or probable IBM according to the European Neuromuscular Center (ENMC) IBM 2011
  • Able to arise from a chair (with or without armrests) without support from another person or device
  • Able to ambulate at least 20 feet / 6 meters with or without assistive device

Exclusion Criteria:

  • Taking > 7.5 mg prednisolone (or equivalent) or on intravenous immunoglobulin (IVIg) or other within the last 3 months. Topical, nasal, and ocular are allowed unless they are being widely applied or the severity of the underlying condition makes them unsuitable in the Investigator's opinion. Local steroid injections are allowed
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Cohort D1

    Single Dose 0.1 mg / kg ABC008

    Drug: ABC008

  • Experimental
    Cohort D2

    Single Dose 0.5 mg / kg ABC008

    Drug: ABC008

  • Experimental
    Cohort D3

    Single Dose 2.0 mg / kg ABC008

    Drug: ABC008

  • Experimental
    Cohort D4

    Single Dose 5.0 mg / kg ABC008

    Drug: ABC008

  • Experimental
    Cohort D5

    X.X mg / kg ABC008

    Drug: ABC008

  • Experimental
    Cohort 6

    Single 2.0 mg / kg ABC008

    Drug: ABC008

  • Experimental
    MAD Phase Cohort 1

    Multiple Dose 0.1 mg / kg ABC008 every 8 weeks

    Drug: ABC008

  • Experimental
    MAD Phase Cohort 2

    Multiple Dose 0.5 mg / kg ABC008 every 8 weeks

    Drug: ABC008

  • Experimental
    MAD Phase Cohort 3

    Multiple Dose 2.0 mg / kg ABC008 every 8 weeks

    Drug: ABC008

Interventions

06

What researchers measure

Primary outcomes

  1. Assessment of Safety and Tolerability

    Characterize the safety and tolerability profile of single (SAD) and multiple (MAD) escalating dose levels of ABC008 in IBM when administered subcutaneously (SC) as measured by the number and severity of treatment emergent adverse events, serious adverse events, and adverse events of special interest, number of dose limiting toxicities.

    Time frame: Through Study Completion an average of 28 weeks for SAD (Single Ascending Dose) phase and 52 weeks for MAD (Multiple Ascending Dose) phase]

Secondary outcomes

  1. Assessment of peak serum concentration (Cmax)

    Assess the peak serum concentration (Cmax) of a single dose of ABC008

    Time frame: Day 1 and throughout the 24 weeks of follow up

  2. Assessment of time to peak serum concentration (Tmax)

    Assess the time to peak serum concentration (Tmax) of a single dose of ABC008

    Time frame: Day 1 and throughout the 24 weeks of follow up

  3. Assessment of terminal half-life (t½)

    Assess the terminal half-life (t½) of ABC008

    Time frame: Day 1

  4. Assessment of area under the concentration versus time curve from time zero to 24 hours post-dose (AUC0-24hr)

    Assess the area under the concentration versus time curve of a single dose of ABC008 from time zero to 24 hours post-dose (AUC0-24hr)

    Time frame: Day 1

  5. Assessment of apparent clearance (CL/F)

    Assessment of apparent clearance (CL/F) of a single dose of ABC008

    Time frame: Day 1 and throughout the 24 weeks of follow up

  6. Assessment of apparent volume of distribution (Vz/F)

    Assessment of apparent volume of distribution (Vz/F) of a single dose of ABC008

    Time frame: Day 1 and throughout the 24 weeks of follow up

  7. Characterization of changes in KLRG1 expressing lymphocytes

    Characterize changes in KLRG1 expressing lymphocytes

    Time frame: Day 1 and throughout the 24 weeks of follow up

  8. Qualitative assessment of [ 89Zr]Zr-Df-crefmirlimab

    Qualitative assessment of \[ 89Zr\]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites as determined by using a visual scoring (VS) system for the time point assessed, the possible scores VS1-VS5

    Time frame: [Through Study Completion, avg. 48 weeks

  9. Assessment of global distribution of [ 89Zr]Zr-Df-crefmirlimab uptake in skeletal muscle

    Assessment of global distribution of \[ 89Zr\]Zr-Df-crefmirlimab uptake in skeletal muscle; Pattern(s) of absolute and relative changes in uptake within various skeletal muscle groups; Homogenous/diffuse, Focal, Mixed, Other

    Time frame: [Through Study Completion, avg. 48 weeks

  10. Assessment of global distribution of [ 89Zr]Zr-Df-crefmirlimab uptake in lymphoid organs

    Assessment of global distribution of \[ 89Zr\]Zr-Df-crefmirlimab uptake in lymphoid organs; Uptake and relative changes in uptake within lymphoid tissue including spleen and lymph nodes as well as other T-cell rich tissues such as bone marrow

    Time frame: [Through Study Completion, avg. 48 weeks

  11. Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab pre and post dosing of ABC008

    Quantitative assessment of \[ 89Zr\]Zr-Df-crefmirlimab uptake and relative changes in uptake within inflamed muscle tissue through Positron Emission Tomography (PET)/computed tomography (CT) imaging pre- and post-dosing with ABC008

    Time frame: [Through Study Completion, avg. 48 weeks

  12. Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab, determined by standardized uptake value (SUV)-based quantitative analysis peak (SUVpeak)

    Quantitative assessment of \[ 89Zr\]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites, and measurement of magnitude of difference observations as determined by standardized uptake value (SUV)-based quantitative analysis peak (SUVpeak)

    Time frame: [Through Study Completion, avg. 48 weeks

  13. Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab, determined by standardized uptake value (SUV)-based quantitative analysis mean (SUVmean)

    Quantitative assessment of \[ 89Zr\]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites, and measurement of magnitude of difference observations as determined by standardized uptake value (SUV)-based quantitative analysis mean (SUVmean)

    Time frame: [Through Study Completion, avg. 48 weeks

  14. Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab, determined by standardized uptake value (SUV)-based quantitative analysis SUV of diseased muscle

    Quantitative assessment of \[ 89Zr\]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites, and measurement of magnitude of difference observations as determined by standardized uptake value (SUV)-based quantitative analysis SUV of diseased muscle

    Time frame: [Through Study Completion, avg. 48 weeks

  15. Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab, determined by standardized uptake value (SUV)-based quantitative analysis SUV reference tissue

    Quantitative assessment of \[ 89Zr\]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites, and measurement of magnitude of difference observations as determined by standardized uptake value (SUV)-based quantitative analysis SUV reference tissue

    Time frame: [Through Study Completion, avg. 48 weeks

  16. Quantitative assessment of [ 89Zr]Zr-Df-crefmirlimab, determined by standardized uptake value (SUV)-based quantitative analysis maximum (SUVmax)

    Quantitative assessment of \[ 89Zr\]Zr-Df-crefmirlimab uptake in involved skeletal muscles including inflamed and non-inflamed sites, and measurement of magnitude of difference observations as determined by standardized uptake value (SUV)-based quantitative analysis maximum (SUVmax)

    Time frame: [Through Study Completion, avg. 48 weeks

07

Study locations

4 sites
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Royal Brisbane
    Herston, Australia
  • Perron Institute
    Perth, Australia
  • Royal North Shore Hospital
    Sydney, Australia
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Jan 2025, 43 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2020
First posted
Dec 9, 2020
StartActual
May 25, 2021
Primary completionActual
Jan 10, 2025
CompletionActual
Jan 10, 2025
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04659031
Lead sponsor
Abcuro, Inc.
Responsible party
Sponsor
First posted
Dec 9, 2020
Start date
May 25, 2021
Primary completion
Jan 10, 2025
Completion
Jan 10, 2025
Last update
Feb 20, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ulviprubart

Start the discussion